Driving Durable Relief in Atopic Dermatitis with Nektar’s REZPEG IL-2 Platform

• Showcasing the unique mechanism of Nektar’s REZPEG IL-2 platform and why it is effective in modulating immune balance
• Highlighting long-term maintenance data from the REZOLVE-AD study to demonstrate sustained efficacy and patient benefit
• Exploring how REZPEG can redefine therapeutic expectations for chronic atopic dermatitis management

Speakers:

Jonathan Zalevsky, Ph.D.

Chief Research & Development Officer

Nektar Therapeutics